In the study population of more than 30,000 people without known liver disease, the proportion of persons with a liver ...

GLP-1 RA helped resolution of steatohepatitis without worsening fibrosis and reduced liver fibrosis without worsening steatohepatitis.

Once liver fibrosis progresses to cirrhosis (stage F4), scarring becomes extensive and irreversible. However, even in ...

A late-stage clinical study showed that this weight loss drug helped 2 out of 3 people with the life-threatening liver ...

A major international study has found that semaglutide, a drug already used to treat type 2 diabetes and obesity, can ...

Roche has introduced the Elecsys PRO-C3 test for evaluating the liver fibrosis severity in individuals with signs of ...

AMSTERDAM — A once daily, 50 mg dose of efruxifermin reduced fibrosis at 96 weeks in patients with compensated cirrhosis due ...

Wegovy (semaglutide) could offer a new option to treat severe liver disease based on new clinical trial evidence. The GLP-1 ...

Once-weekly semaglutide 2.4 mg significantly reduced steatohepatitis and liver fibrosis symptoms among adults with metabolic ...

A phase 3 trial shows that once-weekly semaglutide significantly improves liver histology in patients with metabolic ...

The test enables earlier identification of patients with significant liver fibrosis, potentially improving outcomes through timely management and access to emerging therapies.